Which companies are Gufic Biosciences's closest peers?

The cockpit's peer set: Beijing Foyou Pharma (601089.SS), Aquestive Therapeutics (AQST), Shanghai Fudan Forward S&T (600624.SS), Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), Evolus (EOLS), RPG Life Sciences (RPGLIFE.NS), Zhejiang Chengyi Pharmaceutical (603811.SS), Zhuhai Rundu Pharmaceutical (002923.SZ).

Is Gufic Biosciences expensive compared with its peers?

On ev / sales it trades at 4.4× against a peer median of 3.5×, 9th most expensive of 21 in its peer set.

How has Gufic Biosciences stock performed?

Over six months to 6 Nov 2026 the shares returned +43.9% against -16.4% for the median peer; over one year +32.9%.

← CockpitCompetitor Analysis › GUFICBIO.NS Gufic Biosciences LimitedOpen in the cockpit ↗

Gufic Biosciences LimitedGUFICBIO.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Momentum leader 88

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$454M

US dollars, full cap

Free float

22%

of shares outstanding

$/day

$381,597

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

+4.5 pp

WACC 10.6%

Hurdle

n/a

no reverse DCF

Close · INR₹430.35

1D-0.9%

1W+4.1%

1M+1.9%

3M+6.4%

6M+43.9%

YTD+28.1%

1Y+32.9%

ATR %3.8%

Beta0.64

52w lowhigh8.0% off high

What Gufic Biosciences does

Employees: 2,903

Gufic Biosciences at a glance

Size Gufic Biosciences (GUFICBIO.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $454M, the 880th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹430.35 on 6 Nov 2026.

Performance Over six months the shares gained 43.9%, against -16.4% for the median peer and 0.0% for the India market (cap-weighted) — highest of 20 in its peer set.

Growth Revenue grew 16.7% over the last twelve months (peer median -4.9%); the operating margin is 13.6% (peer median 4.4%).

Valuation It trades at 4.4× enterprise value to sales against a peer median of 3.5× (9th most expensive of 21).

Capital Return on invested capital runs 4.5 points above its cost of capital (10.6% WACC).

Relative performance

Six months, rebased to 100: Gufic Biosciences against the median of its 20 peers (local-currency closes).

Gufic Biosciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	₹9.81B	₹9.44B	₹8.20B	₹8.07B	₹6.91B
Revenue growth	—	+15%	+2%	+17%	—
Gross profit	₹3.57B	₹2.59B	₹2.44B	₹2.41B	₹2.05B
EBITDA	₹1.65B	₹1.54B	₹1.40B	₹1.50B	₹1.40B
Net income	₹735M	₹642M	₹696M	₹861M	₹797M
Free cash flow	n/a	-₹178M	₹271M	-₹1.32B	-₹2.20B
Capital expenditure	n/a	₹312M	₹755M	₹1.13B	₹1.88B
Total debt	n/a	₹4.05B	₹3.36B	₹3.33B	₹3.34B

Quarterly statements and history in the cockpit →

Gufic Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Gufic Biosciences is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Gufic Biosciences is the large dot.

Gufic Biosciences competitors and peer comparison

How Gufic Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Gufic Biosciences against its 20 peers (data as of 6 Nov 2026)
Measure	GUFICBIO.NS	Peer median	Rank in peer set
1-month return	+1.9%	-11.4%	3rd highest of 20
6-month return	+43.9%	-16.4%	highest of 20
Distance from 52-week high	-8.0%	-40.7%	2nd highest of 20
Revenue growth (TTM)	+16.7%	-4.9%	2nd highest of 21
Operating margin	13.6%	4.4%	4th highest of 21
EV / Sales	4.4×	3.5×	9th most expensive of 21
ROIC minus cost of capital	+4.5 pp	-1.6 pp	4th highest of 20
EV / EBITDA	26.1×	15.3×	2nd most expensive of 4
Net debt / EBITDA	2.0×	-0.3×	2nd most indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Gufic Biosciences GUFICBIO.NS	India	$454M	+44%	+17%	14%	4.4×	n/a	n/a
Beijing Foyou Pharma 601089.SS	China	$455M	-24%	+5%	10%	0.2×	n/a	n/a
Aquestive Therapeutics AQST	United States	$454M	-16%	+13%	-114%	10.5×	n/a	n/a
Shanghai Fudan Forward S&T 600624.SS	China	$450M	-4%	-14%	-34%	6.0×	n/a	n/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ	China	$450M	+4%	-21%	8%	4.3×	23.7%	+28.2%
Evolus EOLS	United States	$449M	+7%	+14%	-7%	1.8×	n/a	n/a
RPG Life Sciences RPGLIFE.NS	India	$448M	+2%	+12%	18%	5.8×	n/a	n/a
Zhejiang Chengyi Pharmaceutical 603811.SS	China	$463M	-21%	+7%	19%	3.6×	7.1%	+1.3%
Zhuhai Rundu Pharmaceutical 002923.SZ	China	$464M	-30%	+14%	5%	2.4×	2.5%	-1.3%
Shanghai Jiaoda Onlly 600530.SS	China	$464M	-22%	-2%	-2%	10.4×	33.5%	-0.9%
Teyi Pharmaceutical 002728.SZ	China	$465M	-9%	-7%	7%	3.5×	26.6%	+8.0%
Shaanxi Kanghui Pharmaceutical Co 603139.SS	China	$466M	-20%	-21%	-68%	9.0×	n/a	n/a
Evonile Pharma EVONILE.NS	India	$466M	n/a	-5%	12%	14.5×	46.5%	-1.5%
Harbin Medisan Pharmaceutical 002900.SZ	China	$467M	-13%	-5%	-29%	4.5×	n/a	n/a
Synmosa Biopharma 4114.TWO	Taiwan	$442M	+2%	+11%	11%	2.5×	6.5%	+15.3%
Zhejiang Huakang Pharmaceutical 605077.SS	China	$470M	-39%	+35%	4%	1.2×	n/a	n/a
Kexing Biopharm 688136.SS	China	$470M	-38%	-14%	-12%	3.1×	n/a	n/a
Cachet Pharmaceutical 002462.SZ	China	$471M	-22%	-14%	0%	0.2×	-8.9%	-3.4%
YungShin Global 3705.TW	Taiwan	$474M	+7%	-8%	15%	1.9×	-4.9%	+0.7%
Pulike Biological Engineering 603566.SS	China	$475M	-22%	-9%	5%	2.5×	5.7%	+3.3%
Jiangsu Sihuan Bioengineering 000518.SZ	China	$476M	+7%	-17%	-28%	11.5×	n/a	n/a

Questions

Which companies are Gufic Biosciences's closest peers?: The cockpit's peer set: Beijing Foyou Pharma (601089.SS), Aquestive Therapeutics (AQST), Shanghai Fudan Forward S&T (600624.SS), Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), Evolus (EOLS), RPG Life Sciences (RPGLIFE.NS), Zhejiang Chengyi Pharmaceutical (603811.SS), Zhuhai Rundu Pharmaceutical (002923.SZ).
Is Gufic Biosciences expensive compared with its peers?: On ev / sales it trades at 4.4× against a peer median of 3.5×, 9th most expensive of 21 in its peer set.
How has Gufic Biosciences stock performed?: Over six months to 6 Nov 2026 the shares returned +43.9% against -16.4% for the median peer; over one year +32.9%.